Topic

Feliza Mirasol is the science editor for 

Articles

The partners will aim to establish a platform that enables rapid development of DPI products.

Intertek Teams Up with CrystecPharma on Formulation and Development of Dry Powder Inhaler Products

With these agreements, the respective parties will work to advance therapeutic candidates for treating fibrotic diseases, osteoarthritis, and Alzheimer’s disease.

GSK Enters into Strategic Collaborations with Relation and Muna to Advance Drug Development

The European Commission has approved Novo Holdings' acquisition of Catalent, which includes the related sale of three manufacturing sites to Novo Nordisk, which is also acquiring the Czech Republic manufacturing site of Novavax for $200 million.

Novo Nordisk Gains Manufacturing Sites from Novo Holdings and Novavax while EC Approves Catalent Acquisition

Novartis will in-license PTC's PTC518 program, which has the potential become the first oral disease-modifying therapy for Huntington's disease.

Novartis Enters $2.9 Billion License Agreement with PTC Therapeutics for Huntington’s Disease Development Program

Cheryl Barton is director of PharmaVision, 

Centogene NV and ROPAD consortium publish data from a landmark study identifying genetic variants that may respond to innovative cell and gene therapies.

European Biotechs Unlocking Parkinson’s Disease

Through the agreement, Cambrex will provide accelerated access to clinical development capabilities to Lilly’s biotech collaborators.

Cambrex Enters Agreement with Lilly to Support Biotech Collaborator Manufacturing 

Felicity Thomas is Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

The acquisition will provide Roche with access to Poseida’s GMP manufacturing capabilities and R&D portfolio assets, including cell therapy candidates.

Roche Enters Definitive Merger Agreement to Acquire Poseida Therapeutics

The companies will collaborate to create and test circVec DNA–LNP formulations for use in potential therapeutic applications.

Circio and Certest to Collaborate on LNP Formulations

Under an ongoing partnership with Merck, known as MSD outside of the United States and Canada, Ginkgo Bioworks has achieved the first milestone in a project aimed at improving biologics production.

Merck and Ginkgo Bioworks’ Collaboration to Improve Biologics Manufacturing Has Reached Its First Milestone

Manufacturers of five autologous or matched allogenic cell therapy products have selected TrakCel's  IT platform, OCELLOS, to orchestrate the administration of these therapies, which are approved or expected to be approved in 2024.

Deals, Development and Manufacturing